European contract manufacturing secures more FDA-approved drug deals despite U.S. onshoring efforts and tariffs, signaling a strategic pivot in global pharma production.

Japan's Meiji Seika Pharma's subsidiary Thai Meiji Pharmaceutical has secured regulatory approval for its new facility upgrade, enhancing contract manufacturing capabilities in Southeast Asia.

Chinese biopharma firms have driven a 132% increase in innovative drug out-licensing deals totaling $56.7 billion since early 2026, solidifying China's role as a global biopharmaceutical powerhouse.

The European Economic and Social Committee has issued an opinion advocating for streamlined regulations, increased funding, and a robust ecosystem to prevent Europe from lagging in biotechnology innovation.

Chinese biopharma companies have driven $56.7 billion in innovative drug out-licensing deals since early 2026, marking a 132% increase year-over-year.

Exystat, a leading European CRO specializing in data management and analytics for clinical trials, achieves 77.7% absolute growth rate from 2021 to 2024, positioning it as a top innovator in pharmaceutical outsourcing.

Eli Lilly partners with Hong Kong-based Insilico Medicine on a $2.75 billion AI-driven drug discovery deal for exclusive global rights to preclinical oral therapies in metabolic indications.

Piramal Pharma Solutions announces the successful delivery of its 1,500th antibody-drug conjugate batch from its Grangemouth, UK facility, highlighting its prowess in contract manufacturing.

Chinese innovative drug out-licensing deals surged 132% year-over-year to $56.7 billion across 44 transactions since the start of 2026, underscoring the sector's emergence as the world's second-largest biopharma development hub.

Chinese innovative drug out-licensing deals reached $56.7 billion across 44 transactions since early 2026, up 132% year-over-year, as the sector gains pillar industry status.